Analysis to determine cost-effectiveness of procalcitonin-guided antibiotic use in adult patients with suspected bacterial infection and sepsis.
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Purpose: Results of a study incorporating real-world results into a predictive model to assess the cost-effectiveness of procalcitonin (PCT)-guided antibiotic use in intensive care unit patients with sepsis are reported. Methods: A single-center, retrospective cross-sectional study was conducted to determine whether reductions in antibiotic therapy duration and other care improvements resulting from PCT testing and use of an associated treatment pathway offset the costs of PCT testing. Selected base-case cost outcomes in adults with sepsis admitted to a medical intensive care unit (MICU) were assessed in preintervention and postintervention cohorts using a decision analytic model. Cost-minimization and cost–utility analyses were performed from the hospital perspective with a 1-year time horizon. Secondary and univariate sensitivity analyses tested a variety of clinically relevant scenarios and the robustness of the model. Results: Base-case modeling predicted that use of a PCT-guided treatment algorithm would results in hospital cost savings of $45 per patient and result in a gain of 0.0001 quality-adjusted life-year. After exclusion of patients in the postintervention cohort for PCT test ordering outside of institutional guidelines, the mean inpatient antibiotic therapy duration was significantly reduced in the postintervention group relative to the preintervention group (6.2 days versus 4.9 days, p = 0.04) after adjustment for patient sex and age, Charlson Comorbidity Index score, study period, vasopressor use, and ventilator use. Total annual hospital cost savings of $4,840 were predicted. Conclusion: Real-world implementation of PCT-guided antibiotic use may have improved patients’ quality of life while decreasing hospital costs in MICU patients with undifferentiated sepsis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“C min > MIC”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [253]
In the citing paper
“although a single centre study reported decreased hospital costs associated with PCT-guided antibiotic in medical ICU patient with undifferentiated sepsis [323].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [323]
Citations
Cites
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients
Chertow, G. M., Burdick, E., Honour, M., Bonventre, J. V., & Bates, D. W. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090740 · Cited by 3,408
Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw118 · Cited by 3,061
Bouadma, L., Luyt, C.-E., Tubach, F., Cracco, C., Alvarez, A., Schwebel, C., Schortgen, F., Lasocki, S., Veber, B., Dehoux, M., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61879-1 · Cited by 1,183
van Hal, S. J., Paterson, D. L., & Lodise, T. P. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-12 · Cited by 639
Prkno, A., Wacker, C., Brunkhorst, F. M., & Schlattmann, P. (2013) · Critical Care · doi:10.1186/cc13157 · Cited by 260
Heyland, D. K., Johnson, A. P., Reynolds, S. C., & Muscedere, J. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e31821201a5 · Cited by 213
Cano, E. L., Haque, N. Z., Welch, V. L., Cely, C. M., Peyrani, P., Scerpella, E. G., Ford, K. D., Zervos, M. J., Ramirez, J. A., & Kett, D. H. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.12.013 · Cited by 161
Kip, M. M. A., Kusters, R., IJzerman, M. J., & Steuten, L. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1064934 · Cited by 75
Prevention of vancomycin induced nephrotoxicity: a review of preclinical data
Elyasi, S., Khalili, H., Hatamkhani, S., & Dashti‐Khavidaki, S. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1406-3 · Cited by 63
Research works printed but not linked: 1
- Sim T , BrockhausK, CollinsCDet al Impact of procalcitonin (PCT) on antimicrobial use in intensive care unit patients at a community hospital. Abstract presented at Society for Healthcare Epidemiology of America (SHEA) Spring 2016 Conference: Science Guiding Prevention. Atlanta, GA; 2016 May 18-21.
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Antimicrobial Stewardship Using Biomarkers: Accumulating Evidence for the Critically Ill
Kyriazopoulou, E., & Giamarellos‐Bourboulis, E. J. (2022) · Antibiotics · doi:10.3390/antibiotics11030367 · Cited by 38
S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Update 2025
Brunkhorst, F. M., Adamzik, M., Axer, H., Bauer, M. W., Bode, C., Bone, H.-G., Brenner, T., Bucher, M., David, S., Dietrich, M., et al. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01317-1 · Cited by 47
Kim, H., Roh, Y., & Yoon, S. H. (2021) · Diagnostics · doi:10.3390/diagnostics11050846 · Cited by 35
Metadata
- Authors
- Collins, C. D., Brockhaus, K., Sim, T., Suneja, A., & Malani, A. N.
- Affiliations
- Trinity Health Michigan (US)
- Corresponding author
- Collins, Curtis D
- Venue
- American Journal of Health-System Pharmacy
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-08-01
- Volume
- 76
- Issue
- 16
- Pages
- 1219-1225
- ISSN
- 1079-2082 (ISSN-L)
- 1535-2900
- OpenAlex
- W2966723797
- Cited by
- 25
- References
- 11
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 2 · 2019: 1
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- American Journal of Health-System Pharmacy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- procalcitonin, sepsis, antibiotic stewardship, cost-effectiveness, intensive care unit, antibiotic duration, bacterial infection, quality-adjusted life years, hospital costs, decision-analytic model, real-world implementation
- MeSH terms
- Procalcitonin, Aged, Anti-Bacterial Agents, Bacterial Infections, Cost-Benefit Analysis, Cross-Sectional Studies, Female, Health Plan Implementation, Humans, Intensive Care Units, Male, Middle Aged, Retrospective Studies, Program Evaluation, Biomarkers, Drug Costs, Drug Monitoring, Cost Savings, Hospital Mortality, Hospital Costs, Models, Economic, Sepsis, Quality-Adjusted Life Years, Critical Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis to determine cost-effectiveness of procalcitonin-guided antibiotic use in adult patients with suspected bacterial infection and sepsis. https://app.cochat.ai/papers/10.1093/ajhp/zxz129
- The paper
- Collins, C. D., Brockhaus, K., Sim, T., Suneja, A., & Malani, A. N. (2019). Analysis to determine cost-effectiveness of procalcitonin-guided antibiotic use in adult patients with suspected bacterial infection and sepsis. American Journal of Health-System Pharmacy. https://doi.org/10.1093/ajhp/zxz129
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.